Werbrouck Hadewig, Grijspeerdt Koen, Botteldoorn Nadine, Van Pamel Els, Rijpens Nancy, Van Damme Jo, Uyttendaele Mieke, Herman Lieve, Van Coillie Els
Institute for Agricultural and Fisheries Research, Unit Technology and Food-Product Quality and Food Safety, Brusselsesteenweg 370, 9090 Melle, Belgium.
Appl Environ Microbiol. 2006 Jun;72(6):3862-71. doi: 10.1128/AEM.02164-05.
In this study, a number of Listeria monocytogenes strains of different origins were evaluated for in vitro invasion capacity for various human cell types (monocytic THP-1, enterocytic Caco-2, and hepatocytic HepG2 cells) and for expression levels of specific virulence genes. For THP-1 cells, no differences between clinical and nonclinical L. monocytogenes strains in invasion capacity or in production of the proinflammatory cytokine interleukin-8 (IL-8) were observed, whereas for the Caco-2 and HepG2 cells, significant differences in invasion capacity were noticed. On average, the clinical strains showed a significantly lower invasion capacity than the nonclinical L. monocytogenes strains. Furthermore, it was shown that the clinical strains induce lower IL-8 levels in HepG2 cells than do the nonclinical strains. This observation led us to study the mRNA expression levels of inlA, inlB, and ami, important virulence genes mediating adhesion and invasion of eukaryotic cells, by real-time reverse transcription-PCR for 27 clinical and 37 nonclinical L. monocytogenes strains. Significant differences in inlA and inlB expression were observed, with clinical strains showing a lower expression level than nonclinical strains. These observations were in accordance with in vitro invasion of Caco-2 and HepG2 cells, respectively. The results of this study indicate that differential expression levels of inlA and inlB possibly play a role in the virulence capacities of L. monocytogenes strains. The lower capacity of clinical strains to invade HepG2 cells and to induce IL-8 is possibly a mechanism of immune evasion used by specific L. monocytogenes strains.
在本研究中,对多个不同来源的单核细胞增生李斯特菌菌株进行了评估,检测其对多种人类细胞类型(单核细胞THP-1、肠上皮细胞Caco-2和肝细胞HepG2细胞)的体外侵袭能力以及特定毒力基因的表达水平。对于THP-1细胞,未观察到临床和非临床单核细胞增生李斯特菌菌株在侵袭能力或促炎细胞因子白细胞介素-8(IL-8)产生方面的差异,而对于Caco-2和HepG2细胞,侵袭能力存在显著差异。平均而言,临床菌株的侵袭能力显著低于非临床单核细胞增生李斯特菌菌株。此外,研究表明临床菌株在HepG2细胞中诱导的IL-8水平低于非临床菌株。这一观察结果促使我们通过实时逆转录PCR研究27株临床和37株非临床单核细胞增生李斯特菌菌株中inlA、inlB和ami这三个介导真核细胞黏附和侵袭的重要毒力基因的mRNA表达水平。观察到inlA和inlB表达存在显著差异,临床菌株的表达水平低于非临床菌株。这些观察结果分别与Caco-2和HepG2细胞的体外侵袭情况相符。本研究结果表明,inlA和inlB的差异表达水平可能在单核细胞增生李斯特菌菌株的毒力能力中发挥作用。临床菌株侵袭HepG2细胞和诱导IL-8的能力较低,可能是特定单核细胞增生李斯特菌菌株用于免疫逃避的一种机制。